中国社区医师
中國社區醫師
중국사구의사
Chinese Community Doctors
2014年
34期
18-19
,共2页
肝硬化门静脉高压症%临床治疗%缬沙坦
肝硬化門靜脈高壓癥%臨床治療%纈沙坦
간경화문정맥고압증%림상치료%힐사탄
Liver cirrhosis and portal hypertension%Clinical treatment%Valsartan
目的：探讨肝硬化门静脉高压症的临床治疗方法。方法：收治肝硬化门静脉高压症患者40例，将其均分为对照组与观察组，对对照组实施常规的治疗，观察组在常规治疗的基础上，加用缬沙坦治疗，在患者的治疗前后应用彩色多普勒超声仪对其门静脉及脾静脉的流速与内径进行检测，并在整个治疗过程中，对患者的心率、血压、肝肾功能、血常规等予以监测。结果：观察组的门静脉与脾静脉流速、内径与治疗前相比具有明显的变化，并且差异具有统计学意义(P＜0.05)；患者的心率、血压没有明显的变化，同时患者的肝肾功能、血常规等没有受到明显的损害；而对照组的各项指标都没有明显的变化。结论：将缬沙坦应用于肝硬化门静脉高压症患者的治疗中，能够有效地提升患者的血流速度，降低患者的门静脉压力，并不会对患者的肝肾功能、血常规、心率、血压等产生影响，具有较好的临床治疗效果。
目的：探討肝硬化門靜脈高壓癥的臨床治療方法。方法：收治肝硬化門靜脈高壓癥患者40例，將其均分為對照組與觀察組，對對照組實施常規的治療，觀察組在常規治療的基礎上，加用纈沙坦治療，在患者的治療前後應用綵色多普勒超聲儀對其門靜脈及脾靜脈的流速與內徑進行檢測，併在整箇治療過程中，對患者的心率、血壓、肝腎功能、血常規等予以鑑測。結果：觀察組的門靜脈與脾靜脈流速、內徑與治療前相比具有明顯的變化，併且差異具有統計學意義(P＜0.05)；患者的心率、血壓沒有明顯的變化，同時患者的肝腎功能、血常規等沒有受到明顯的損害；而對照組的各項指標都沒有明顯的變化。結論：將纈沙坦應用于肝硬化門靜脈高壓癥患者的治療中，能夠有效地提升患者的血流速度，降低患者的門靜脈壓力，併不會對患者的肝腎功能、血常規、心率、血壓等產生影響，具有較好的臨床治療效果。
목적：탐토간경화문정맥고압증적림상치료방법。방법：수치간경화문정맥고압증환자40례，장기균분위대조조여관찰조，대대조조실시상규적치료，관찰조재상규치료적기출상，가용힐사탄치료，재환자적치료전후응용채색다보륵초성의대기문정맥급비정맥적류속여내경진행검측，병재정개치료과정중，대환자적심솔、혈압、간신공능、혈상규등여이감측。결과：관찰조적문정맥여비정맥류속、내경여치료전상비구유명현적변화，병차차이구유통계학의의(P＜0.05)；환자적심솔、혈압몰유명현적변화，동시환자적간신공능、혈상규등몰유수도명현적손해；이대조조적각항지표도몰유명현적변화。결론：장힐사탄응용우간경화문정맥고압증환자적치료중，능구유효지제승환자적혈류속도，강저환자적문정맥압력，병불회대환자적간신공능、혈상규、심솔、혈압등산생영향，구유교호적림상치료효과。
Objective:To explore the clinical treatment of liver cirrhosis with portal hypertension.Methods:40 patients with liver cirrhosis with portal hypertension were selected.They were randomly divided into the control group and the observation group.The control group were treated with routine treatment,and the observation group was treated with valsartan on the basis of conventional therapy.Before and after treatment,the velocity and diameter of portal veins and splenic veins were examined by color Doppler ultrasound.In the whole course of treatment,patients heart rate,blood pressure,liver and kidney function,blood routine were monitoring.Results:In the observation group,compared with before treatment,portal vein and splenic vein flow velocity,diameter had the obvious change,and the difference had statistical significance(P<0.05);The patient's heart rate,blood pressure did not change obviously,the liver and kidney function and blood routine in patients were without apparent damage;in the control group, the indexes of patients had no obvious change.Conclusion:Valsartan used in liver cirrhosis with portal hypertension patients can effectively improve the blood flow velocity of patients and reduce portal pressure of patients,and it has no effect on the liver and kidney function,toutine blood test,heart rate,blood pressure and so on.It has better clinical therapeutic effect.
